Potential solutions for manufacture of CAR T cells in cancer immunotherapy
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Potential solutions for manufacture of CAR T cells in cancer immunotherapy
Authors
Keywords
-
Journal
Nature Communications
Volume 13, Issue 1, Pages -
Publisher
Springer Science and Business Media LLC
Online
2022-09-05
DOI
10.1038/s41467-022-32866-0
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Decade-long leukaemia remissions with persistence of CD4+ CAR T cells
- (2022) J. Joseph Melenhorst et al. NATURE
- Rapid manufacturing of non-activated potent CAR T cells
- (2022) Saba Ghassemi et al. Nature Biomedical Engineering
- CAR T cells as a second-line therapy for large B-cell lymphoma: a paradigm shift?
- (2022) Jason Westin et al. BLOOD
- Single-cell antigen-specific landscape of CAR T infusion product identifies determinants of CD19-positive relapse in patients with ALL
- (2022) Zhiliang Bai et al. Science Advances
- The clinical pipeline for cancer cell therapies
- (2021) Samik Upadhaya et al. NATURE REVIEWS DRUG DISCOVERY
- Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors
- (2020) Enli Liu et al. NEW ENGLAND JOURNAL OF MEDICINE
- Human chimeric antigen receptor macrophages for cancer immunotherapy
- (2020) Michael Klichinsky et al. NATURE BIOTECHNOLOGY
- Classification of T-cell activation via autofluorescence lifetime imaging
- (2020) Alex J. Walsh et al. Nature Biomedical Engineering
- Characteristics of anti-CD19 CAR T cell infusion products associated with efficacy and toxicity in patients with large B cell lymphomas
- (2020) Qing Deng et al. NATURE MEDICINE
- Bispecific anti-CD20, anti-CD19 CAR T cells for relapsed B cell malignancies: a phase 1 dose escalation and expansion trial
- (2020) Nirav N. Shah et al. NATURE MEDICINE
- Tumor burden, inflammation, and product attributes determine outcomes of axicabtagene ciloleucel in large B-cell lymphoma
- (2020) Frederick L. Locke et al. Blood Advances
- Genome-edited, donor-derived allogeneic anti-CD19 chimeric antigen receptor T cells in paediatric and adult B-cell acute lymphoblastic leukaemia: results of two phase 1 studies
- (2020) Reuben Benjamin et al. LANCET
- Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia
- (2018) Joseph A. Fraietta et al. NATURE MEDICINE
- Detection of human disease conditions by single-cell morpho-rheological phenotyping of blood
- (2018) Nicole Toepfner et al. eLife
- Automated Manufacturing of Potent CD20-Directed Chimeric Antigen Receptor T Cells for Clinical Use
- (2017) Dominik Lock et al. HUMAN GENE THERAPY
- Automated manufacturing of chimeric antigen receptor T cells for adoptive immunotherapy using CliniMACS Prodigy
- (2016) Ulrike Mock et al. CYTOTHERAPY
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started